Genentech: FDA Grants Priority Review For Tecentriq - Quick Facts

Genentech, a member of the Roche Group (RHHBY.PK), said FDA has granted priority review for Tecentriq as adjuvant treatment for certain people with early non-small cell lung cancer. The company's application is based on disease-free survival results from an interim analysis of the phase III IMpower010 study. Results from the trial were presented at the ASCO Annual Meeting.

The FDA is reviewing the application under the Real-Time Oncology Review pilot program, and is anticipated to make a decision on approval by December 1, 2021.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT